Quick Dispatch:
Your tirzepatide cardiovascular outcomes trial Tirzepatide and Cardiovascular Outcomes in Patients With Ventricular Tachycardia and Systolic Heart Failure orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide cardiovascular outcomes trial Tirzepatide and Cardiovascular Outcomes in Patients With Ventricular Tachycardia and Systolic Heart Failure ships.
Need Help?
Questions about tirzepatide cardiovascular outcomes trial Tirzepatide and Cardiovascular Outcomes in Patients With Ventricular Tachycardia and Systolic Heart Failure, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide cardiovascular outcomes trial Tirzepatide and Cardiovascular Outcomes in Patients With Ventricular Tachycardia and Systolic Heart Failure in your area.
SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide
21.28
Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT‐1 trial - Hankosky
22.90
🚨 Breaking News: Real-World Data Comparing Semaglutide and Tirzepatide on Cardiovascular Outcomes
21.13
Original Article: Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes (SURPASS-CVOT)
26.04
In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. , , Read the full SURPASS-CVOT
25.64
Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM
21.04
Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism
21.58
